全国免费服务热线:021-64330607 服务时间 9:00-22:00 新浪微博 腾讯微博 注册 当前用户:[USERNAME],用户ID:[USERID] 用户中心 退出 收藏本页

american journal of pathology

来源:作者:热度:Loading...日期:2014-01-23, 06:00 PM

期刊名称 american journal of pathology 

期刊缩写 AM J PATHOL   
学科分类 医学、生命科学 

出版周期 月刊   
审稿速度 1 个月 (平均) 

投稿命中率 25 % (均值)   
期刊主页 http://ajp.amjpathol.org/   
ISSN 号 (printed): 0002-9440 (electronic): 1525-2191   
IF 趋势   2005     2006     2007     2008     2009     2010     2011     2012    
             5.796     5.917    5.487    5.697    5.673    5.224     4.89      4.522   
被收录情况  1. Science Citation Index 
                   2. Science Citation Index Expanded 
                   3. Current Contents - Clinical Medicine 
                   4. Current Contents - Life Sciences 
                   5. BIOSIS Previews   
PubSci评语 审稿速度有点慢,网上列明的收费点很多,补充数据、彩色图片、灰色图片还有图表都要收费,除此之外,还有版面费。   
期刊简介 The American Journal of Pathology是美国调查病理学学会的正式刊物,致力于发表疾病在细胞和分子生物学水平方面的高水平研究成果。重点关注人类疾病以及在相关动物模型上用细胞学、分子、动物、生物、化学以及免疫学方式得到的研究结果。   
投稿注意事项 特别提醒:补充数据文件1MB以内需要交纳95美元,1MB以上每增加1MB多交纳95美元。每张彩图收费550美元,黑白或灰色图收费50美元。每张压缩图表收费50美元。印刷形式的论文,每页交纳95美元的版面费,发展中国家的作者符合条件的可以减免。如果作者选择Open Choice发表论文,则需额外交纳1500美元。
一般注意事项:
Instructions to Authors

The American Journal of Pathology, the official journal of the American Society for Investigative Pathology (ASIP) and published by Elsevier, Inc., seeks to publish high-quality original papers on the cellular and molecular biology of disease. The Editors accept manuscripts that advance basic and translational knowledge of the pathogenesis, classification, diagnosis, and mechanisms of disease, without preference for a specific analytic method. High priority is given to studies on human disease and relevant experimental models using cellular, molecular, animal, biological, chemical, and immunological approaches in conjunction with morphology. 

Manuscript Categories. Regular Articles are categorized in the Table of Contents according to the following research topics: Animal Models; Biomarkers, Genomics, Proteomics, and Gene Regulation; Biophysical Imaging and Computational Biology; Cardiovascular, Pulmonary and Renal Pathology; Cell Injury, Repair, Aging and Apoptosis; Epithelial and Mesenchymal Cell Biology; Gastro-intestinal, Hepatobiliary and Pancreatic Pathology; Growth Factors, Cytokines, and Cell Cycle Molecules; Immunopathology and Infectious Diseases; Matrix Pathobiology; Metabolic, Endocrine and Genitourinary Pathobiology; Molecular Pathogenesis of Genetic and Inherited Diseases; Musculoskeletal Pathology; Neurobiology; Stem Cells, Tissue Engineering and Hematopoietic Elements; Tumori-genesis and Neoplastic Progression; and Vascular Biology, Atherosclerosis and Endothelium Biology. Not all topic areas will appear in each issue, as this is dependent on the content of original research accepted for publication. Upon acceptance, authors will be asked for their preference of topic category assignment; however, the Editors will make the final determination regarding topic category placement.

Short Communications are intended to provide a forum for the rapid publication of timely and significant findings, in brief. Manuscripts in this category should be concise but definitive, may be more descriptive and less mechanistic than Regular Articles, and must not exceed 12 double-spaced typed pages (excluding references and legends) and a maximum of 4 combined figures and tables. Categorization of manuscripts in this category is at the Editor's discretion.

In addition to original research articles, the Journal publishes articles categorized as Reviews, Mini-Reviews, Biolological Perspectives,and Commentaries. Authors who wish to publish a Review or Mini-Review should send their curriculum vitae along with an outline of the proposed article for prior approval by the Editor-in-Chief. Reviews have a maximum of 6,000 words, 100 references, and 4 tables or figures (one of which is mechanistic); Mini-Reviews have a maximum of 4,000 words, 50 references, and 2 tables or figures (one of which is mechanistic). Biological Perspectives are submitted by invitation only and provide streamlined, mechanistic insight into the current state of research in the discussed topic. Commentaries are submitted by invitation only and relate to a concurrently published manuscript. All invited papers are subject to the same review process as unsolicited articles.

Review Process. The Editors perform an initial evaluation on all submissions to determine whether they believe the manuscript will achieve a sufficient priority score to warrant publication. Priority is determined by the Editors' assessment of the manuscript relative to other papers being considered. The aim is that expeditious treatment will enable authors to submit their manuscript elsewhere as soon as possible without suffering unnecessary delays. For manuscripts accepted for external review, the Editor-in-Chief assigns manuscripts to Associate Editors according to their expertise. The Associate Editor will solicit reviewers (typically, two external reviews are sought). Authors are encouraged to identify up to five potential reviewers. Authors may also request that specific reviewers not be used due to prior collaborations, known conflicts of interest, or direct competition. The Editors will make every effort to respect requests that are well-founded; however, the Editors do have the authority to utilize such a reviewer if it is necessary for expert peer review. It is the practice of the Journal to conduct a blinded peer-review process. The peer-review process is kept completely confidential; it is considered a violation of this confidentiality for authors to identify or attempt to communicate directly with peer reviewers or Associate Editors regarding their manuscript. All editorial communications should be directed through the Editorial Office at ajp@asip.org. The reviewer comments and Associate Editor's recommendation are evaluated by the Editor-in-Chief for disposition and transmittal to the authors. Every effort is made to complete the review process within 35 days of the date received.

Review Decisions. Only a portion of manuscripts will be accepted for publication. A number of worthy manuscripts will be rejected based on priority. The Journal will advise authors whether the manuscript is accepted, acceptable with revisions, rejected but encourage resubmission (after major revision), or rejected. A manuscript may be returned to the authors without outside review if the Editors find it inappropriate for publication in this Journal. Appeals (rebuttals) to editorial decisions must be submitted within 60 days to be considered.

Journal Scientific Integrity Policy. The Journal has developed principles for defining proper conduct and scientific misconduct as well as procedures for handling such matters. General guidelines are described below; detailed information can be viewed at  http://www.journals.elsevierhealth.com/periodicals/ajpa/content/integrity. To report suspected misconduct relating to authors, reviewers, or Editors, send written complaint to the Editorial Office at The American Journal of Pathology, 9650 Rockville Pike, Bethesda, Maryland, USA 20814-3993 or ajp@asip.org. Issues relating to staff conduct should be directed to the ASIP Executive Officer at American Society for Investigative Pathology, 9650 Rockville Pike, Bethesda, Maryland, USA 20814-3993 or email 
mesobel@asip.org 

Author Conduct. Authorship is defined as 1) substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2) drafting the manuscript or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3. When submitting a manuscript to the Journal, the corresponding author takes responsibility on behalf of all authors for the authorship, authenticity, and integrity of the research being reported. Authors should take special care that manuscripts submitted to the Journal are prepared in accordance with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see   http://www.icmje.org); in particular the ethical considerations regarding authorship, conflicts of interest, redundant publication, and treatment and confidentiality of research subjects should be carefully adhered to. Additionally, the Journal takes great care to secure the confidentiality and integrity of the peer-review process; it is considered a violation of this confidentiality for authors to identify or attempt to communicate directly with peer reviewers or Associate Editors regarding their manuscript. All editorial communications should be directed through the Editorial Office at ajp@asip.org. The Editors will consider any deliberate ethical violation in either the reported research or the manuscript preparation and review to be actionable misconduct, the potential results of which may be manuscript rejection or public article retraction, reporting of conduct to the authors' governing institutions, and/or the denial to consider any future submissions to the Journal. Willful misconduct does not include incidents of honest misjudgment or inadvertent error. Detailed information regarding possible misconduct can be found in the Journal Scientific Integrity Policy at   http://www.journals.elsevierhealth.com/periodicals/ajpa/content/integrity.

Manuscript Submission. Manuscripts should be submitted online via the Rapid Review system ( http://www.rapidreview.com/ASIP2/CALogon.jsp). Detailed instructions on preparing and submitting files can be found on the author submission website at the above URL. Authors having difficulty submitting files online should complete the online submission form on Rapid Review to receive the assigned manuscript number. With the manuscript number clearly noted, electronic files (manuscript text, figures, tables, and supplemental data) should be emailed to the Editorial Office at ajp@asip.org or sent on disk by mail to: The American Journal of Pathology, 9650 Rockville Pike, Bethesda, Maryland, USA 20814-3993. The cover letter must state any conflicts of interest (both financial and personal), affirm that the manuscript has not been published previously and is not being considered concurrently by another publication, and affirm that all authors and acknowledged contributors have read and approved the manuscript. Submissions will be ineligible for review if previously published in any form (print or online) other than as an abstract. This includes any public posting of raw manuscripts or pre-reviewed material. A non-refundable manuscript processing fee of US$50 is required with submission. This fee should be paid electronically at the time of submission. Manuscripts arising from research in developing countries may be eligible for waiver of the submission fee only if all authors are located in a qualifying country (waiver must be applied for at time of submission; for a list of eligible countries, see Group A and Group B countries at   http://www.who.int/hinari/eligibility/en). Otherwise, manuscript submission fees will not be waived.

Manuscript Preparation. Manuscripts should be prepared in the style of the Journal and in accordance with The Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see   http://www.icmje.org). The preferred file format for text is MS Word. Standard abbreviations can be found in the CSE Style Manual (7th ed., 2006). All pages of the manuscript should be double-spaced and numbered (including references, tables and figure legends); line numbers should also be included to assist reviewers in making comments. Other formatting specifications (eg, font size and type, margin settings, etc) are left to the authors' discretion, as papers accepted for publication will be reformatted according to the print specifications of the Journal. Manuscripts not prepared in accordance with the submission guidelines detailed below may be returned to the authors. Authors are encouraged to include a list of nonstandard abbreviations to aid reviewers; however, the Journal does not publish abbreviations or keywords as part of the final article. In addition, authors should be ready to comply with Editors' requests for copies of any similar works in preparation, copies of cited manuscripts that are submitted or in press, and/or supporting manuscript data (eg, data not shown but summarized in the manuscript) that may aid the review process.

Title Page(s). The title page(s) must include a concise title accurately reflecting the findings of the work; full names (not initials) of all authors; department, institution and address where the research was performed; number of text pages, tables, and figures; a short running head (40 characters or less); grant numbers and sources of support (including departmental or institutional funding when no extramural funding was received); name, address, phone, fax, and email of the corresponding author; and name and address of author who should receive reprint requests if different from corresponding author. If an author changes employment after the study was performed, the new affiliation information for that author should be included as a footnote. Any relationships (eg, employment, consultancies, board membership, stock ownership, funding, honoraria, expert testimony, patents or royalties, travel reimbursements, industry-supplied free reagents, etc) with any organization or entity having a direct financial or personal interest in the subject matter or materials discussed in the article should also be clearly stated.

Abstract. An abstract of 220 words or less should be prepared on a separate page and should be intelligible to the general reader without reference to the text. The abstract should clearly summarize the background, methodology, results, and significance of the study. Abbreviations and citations should be avoided.

Text. The remaining sections of the text, which should include Introduction, Materials and Methods, Results, Discussion, and Acknowledgments (in this order), need not begin on new pages. Commonly-abbreviated terms should be spelled out in their first occurrence and then may be referenced in abbreviation through the remainder of the manuscript. The Journal requires the use of official gene and protein symbols, to facilitate standardization of scientific communication. Consult the Human Genome Organisation Gene Nomenclature Committee website (  http://www.genenames.org/) for gene names and symbols and UniProt (  http://www.uniprot.org) for protein names and symbols. For a complete list of other approved nomenclature organizations (eg, bacteria, viruses, mice), please contact the Editorial Office. 

For Materials and Methods, authors should describe experimental and statistical methods in enough detail that other researchers can replicate results and evaluate claims. In general, inclusion of method or reagent details as supplementary material is not acceptable. In addition, linking to protocols online is not permissible as there is no guarantee that the information will remain unchanged and accessible in perpetuity. The sequences of oligonucleotides, if not previously published, should be provided. Novel DNA or protein sequences should be deposited to an appropriate database (eg, Genbank, EMBL, SWISS-PROT), with the accession numbers included in the manuscript. When providing supplier information for materials sources, company name and location (city and state, or city and country) should be provided. Website references to company information are not permitted. All novel materials and the procedures to prepare them should be described in sufficient detail to allow their reproduction (eg, DNA constructs, analytical software). Materials that are approved for investigational-use only should be clearly indicated. Special care should be taken to assure that statistical methods are appropriate. 

Publication in the Journal implies that the authors agree, upon reasonable request, to share any materials or data that are integral to the results presented in the article, including whatever would be necessary for a skilled investigator to verify or replicate the claims. This may include original software code used in the data analysis. Agreement o share reagents or software code does not preclude the authors from implementing a Data Use Agreement. Authors must disclose upon submission any restrictions on the availability of materials or information, such as for patented or dual-purpose materials. 

Reporting guidelines for specific study designs (eg, randomized controlled trials) can be found online in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see   http://www.icmje.org). Authors must affirm that the research protocol was approved by the appropriate institutional review boards or ethics committees for human (including use of human cells or tissues) or animal experiments and that all human subjects provided appropriate informed consent and/or that regulations concerning the use of animals in research were adhered to. If race/ethnicity is reported, authors should state who determined race/ethnicity, how the options were defined, and why race/ethnicity was important in the study. Authors should be prepared to provide study protocol number(s) if requested.

Authors should obtain permission from all individuals named (by full name) in the Acknowledgments who contributed substantially to the work reported (eg, data collection, analysis, or writing/editing assistance) but did not fulfill the authorship criteria. Likewise, authors should receive permission from all individuals named as sources for personal communication or unpublished data. Such permissions should be affirmed by the corresponding author in the cover letter. A list of individual author contributions may be placed in this section as a separate paragraph.

References. References should begin on a new page, be double-spaced and numbered in order of citation in the text, including citations in tables and figure legends. Citations that first appear in tables, figures, or supplemental data should be numbered according to the item's first call out in the text; a separate reference list should not be prepared for supplemental data. Complete author citation is required (use of "et al" is not acceptable). References should conform to the style of the Journal. Examples follow:
Journals: Cecena G, Wen F, Cardiff RD, Oshima RG: Differential sensitivity of mouse epithelial tissues to the polyomavirus middle T oncogene. Am J Pathol 2006, 168:310-320
Books: Fishman AP: Pulmonary Hypertension and Cor Pulmonale. Pulmonary Diseases and Disorders. Edited by Fishman AP. New York, McGraw-Hill, 1988, pp. 999-1048 
In press: To be used only for papers accepted for publication. Cite as for journal with (in press) in place of volume and page numbers. Include digital object identifier (doi) when available for online early publications. 
Submitted papers/unpublished data: Cite in text only. 
Web sites: Cite in text only. See Data Supplements section below for proper use of web site references. Use the doi when available. Include the name of the institution sponsoring the web site, URL address with direct linkage to the referenced information, and date of last access.

Tables. Tables should be typed double-spaced and submitted after the main text on separate pages, as part of the manuscript. The preferred file format for Tables is MS Word; figure file formats (including those embedded in the text) are unacceptable. Tables should be black and white text only and should not include figures or other non-typeset images. Color or gray shading is not permitted. Emphasis may be represented by bold, italics, and underlining. Nucleotide sequences should be capitalized, not lowercase. Table footnotes should use the following sequential symbols: *, †, ‡, §, ¶ ?; these may be doubled up if needed. All symbols and abbreviations in the table should be defined in the footnotes. 

Figures. Authors should give considerable care in preparing figures. Resolution and quality of submitted images is the responsibility of the author; as a routine, the Journal does not provide figure enhancement services. Images (such as graphs and schematics) should have a white background; color, black, or gray is generally unacceptable. Authors are encouraged to carefully consider whether bar or line graphs should be submitted in grayscale or color, paying special attention to the ability of a reader to distinguish between different data points. Figures may consist of multiple related panels (labeled A, B, C, etc) described under one figure legend. Each figure (with all of its related panels) should be arranged on a single page as it should appear in final publication. Text labels in figures should use a professional looking font such as Arial; Comic Sans should be avoided. Figure labels should appear in the upper left corner as uppercase letters; refrain from using sub-labels (Aa, Ab, Ai, Aii, A1, A2, etc) or titles for each panel label; panels should be labeled chronologically from left to right. Figure panels submitted on separate pages will be arranged at the publisher's discretion. If figures are to be published in black and white, they should be submitted for review in black and white. Figures should be sized to fit one column (8 cm) or two columns (17 cm). Maximum page length is 22.5 cm. Figures deviating from these dimensions will be sized at the publisher's discretion. Unwanted background material should be excluded, and edges should be straight.

Preparation of Images (Ethics): Taking photographs of the same source under varied fields of view, light intensity, magnifications, or contrast conditions without disclosing that the data are not unique to the present study constitutes suspect scientific conduct. Further, unless serial sections are used, the publication of identical-appearing images labeled with different staining techniques in different papers raises legitimate questions. Finally, reuse of one's data (ie, "self-plagiarism") is a copyright violation if the authors signed over copyright to the publisher; the reuse of such copyrighted images is at the sole discretion of the publisher, with proper attribution of the original publication a requirement of reuse. No specific feature within an image may be enhanced, obscured, moved, removed, or introduced. The grouping of images from different parts of the same gel or blot, or from different gels or blots, fields, or exposures must be made explicit by the arrangement of the figure (eg, using dividing lines) and in the figure legend. Adjustments of brightness, contrast, or color balance are acceptable only if they are applied to the whole image, whether experimental or control image, and as long as they do not obscure or eliminate any information present in the original (Portions adapted with permission from the JCB). Any evidence of inappropriate manipulation may prompt the Editors to request an explanation and access to original data, which the authors must make available. Information can be found in the Journal Scientific Integrity Policy at  http://www.journals.elsevierhealth.com/periodicals/ajpa/content/integrity

Digital Art: Digital figure files are required for submission. The American Journal of Pathology's requirement for color images is RGB (Red, Green, Blue) color mode. Images submitted in RGB will retain the vivid reds, greens, and blues of the original digital files for online publication. Authors should therefore submit all figures (for both new and revised manuscripts) in the RGB color mode. The preferred file formats for digital figures are PDF, TIFF, and EPS. PPT is discouraged due to the potential for font and layout changes occurring after opening in different versions of PowerPoint. For detailed instructions on preparing digital art for submission or production, visit http://www.elsevier.com/wps/find/authorsview.authors/authorartworkinstructions or contact the Editorial Office (ajp@asip.org). 

Figure Legends. Figure legends should be submitted as part of the manuscript (separate from the figure files) and should describe any staining method and degree of magnification. If the exact scale is critical, scale bars should be used on the photograph and specified in the legend. Figure legends should adequately describe all descriptors: arrows, arrowheads, scale bars, insets, asterisks, boxes/circles/etc in line graphs, and any other notations. Descriptive text, rather than graphics inserted into the text, should be used when possible (eg, closed circles, open boxes, hatched bars, etc); alternatively, a legend key should be included in the figure. Statistical significance (eg, P values) should be clearly defined by asterisks (*, **, ***) or by other sequential symbols: *, †, ‡, §, ¶, ?; these may be doubled up if needed. P values should be labeled by symbol in the image, with definitions appearing only in the leg end. Labeling of data as not significant (NS) is unnecessary. All abbreviations should also be defined. 

Data Supplements and Non-Traditional Media. Figures and tables that are critical to the evaluation and understanding of the research presented, but which cannot be accommodated via the print medium (eg, video), will be considered part of the manuscript submission and will be published on the Journal website if the manuscript is accepted. Supplemental figures (PDF, TIFF, or EPS), tables (MS Word or Excel), and legends (MS Word) should be prepared as above. Supplemental material published on the Journal website is subject to the same copyright as applies to the printed article. Online data will remain associated with its article and is not subject to any modifications or updates after publication. Authors of accepted manuscripts will be charged US$95 per supplemental data file to be published on the Journal website (up to 1MB; files over 1MB will be charged an additional US$95 per megabyte). Authors are therefore encouraged to minimize the size of their supplemental data files.

Complex data sets such as microarray data and gene sequences should be deposited in a reliable public archive. Microarray repositories should comply with the Minimum Information About a Microarray Experiment (MIAME) guidelines ( http://www.mged.org/Workgroups/MIAME/miame_1.1.html). Examples include Gene Expression Omnibus ( http://www.ncbi.nlm.nih.gov/geo) and Array Express (  http://www.ebi.ac.uk/arrayexpress). Tissue microarray data exchange specifications can be found at   http://www.biomedcentral.com/1472-6947/3/5. Otherwise, the data may be published as supplemental data on the Journal's website (  http://ajp.amjpathol.org). 

Other materials that are not required to understand and evaluate the article may be stored on an institutional website and referenced as a URL within the manuscript text. In this case, the authors must assume responsibility for maintaining a live, unrestricted link to the material from the URL published within the article, in perpetuity. Failure to maintain a live, unrestricted link may result in retraction of the article by the Editors. Material that has been published previously (print or online) is not acceptable for posting as supplementary data. Instead, the appropriate reference(s) to the original publication should be made in the text and references. 

The Editors will make the final determination as to whether a given data set is essential to the manuscript and whether they will require publication of the material on the Journal website. Failure to relinquish required materials for online publication can result in the reversal of a manuscript's acceptance. 

Copyright. Copyright of published manuscripts is held by the American Society for Investigative Pathology, which must receive the assignment of copyright from the authors of accepted manuscripts. For US government employees, the above assignment applies only to the extent allowable by law. For detail, see   http://www.asip.org/pubs/ajprights.pdf. Publishing in The American Journal of Pathology automatically places authors in compliance with NIH Public Access Policy (see   http://publicaccess.nih.gov/submit_process.htm, Submission Method A). Any article noted as being funded by NIH, HHMI, Wellcome Trust, or MRC is deposited in PubMed Central (PMC), to be made available to the public twelve months after final print publication (unless the funding agency stipulates a sooner release date, such as six months). Authors therefore should NOT complete a separate deposit of their material but will be contacted by PubMed Central for grant verification once the article has been received by the PMC article system. For information on how to cite articles in NIH grant applications, please visit   http://www.asip.org/pubs/AuthorNotice.cfm

Contact permissions@elsevier.com regarding permission to deposit manuscripts in other government-sponsored repositories in cases where The American Journal of Pathology does not have a system in place to automatically deposit materials on behalf of their authors. Deposit of accepted or published manuscripts in any non-AJP repository without prior permission by the Journal is a violation of copyright.

Embargo Policy. All information regarding the content of submitted or accepted manuscripts is strictly confidential. Information contained in or about accepted articles cannot appear in print, audio, video, or digital form or be released by the news media until the Journal embargo date has passed, not to exceed the publication date of the article. For detailed information on embargo release dates or for news media requests for preprint copies of specific articles, contact asipproduction@elsevier.com

Financial Disclosure and Conflicts of Interest. All authors must disclose any current or former relationships (eg, employment, consultancies, board membership, stock ownership, funding, honoraria, expert testimony, patents or royalties, travel reimbursements, industry-supplied free reagents, etc) with any organization or entity having a direct financial or personal interest in the subject matter or materials discussed in the article. Authors should err on the side of full disclosure and should contact the Editorial Office if they have questions or concerns. This information should be provided at the time of submission and reiterated as part of copyright assignment. Failure to do so may result in manuscript rejection or editorial retraction of the article. Further information can be found in the Journal Scientific Integrity Policy at   http://www.journals.elsevierhealth.com/periodicals/ajpa/content/integrity. Upon manuscript acceptance, all coauthors will be instructed to formally disclose all potential conflicts. 

Publication Charges
Figure and Table Charges: Authors will be charged US$550 per color figure, US$50 per black & white or grayscale figure, and US$50 per composed table, per printed page (ie, figures or tables necessitating more than one printed page will incur an additional charge). Corresponding authors of published manuscripts who are current, dues-paying regular members of ASIP at the time of submission will receive one free color figure as a benefit of membership; page charges will not be waived for ASIP members. 
Page Charges: Authors will be charged US$95 per printed page. Manuscripts arising from research in developing countries may be eligible for waiver of publication charges only if all authors are located in a qualifying country (for a list of eligible countries, see Group A and Group B countries at   http://www.who.int/hinari/eligibility/en). Otherwise, page charges will not be waived, except for solicited editorials. Approval of Fees and Invoicing: A summary of publication charges (figures, tables, and supplemental data) will be presented to the corresponding author of accepted manuscripts for approval prior to publication; final page charges cannot be determined until final publication. Color figure charges will not be waived, but color figures may be published in black and white, pending editorial approval. Requests for black and white figure publication must be made prior to execution of the publication charge approval form to avoid color charges. A final invoice will be presented immediately after publication; full payment is expected at that time. Failure to pay publication charges may result in the authors' inability to publish future articles in The American Journal of Pathology. 

Open Choice. In addition to publication charges outlined above, authors may elect to participate in the Journal's Open Choice program. Articles published under Open Choice will become immediately accessible on the Journal website upon publication, without the twelve-month subscriber-only access delay. Authors wishing to participate should contact the Editorial Office following manuscript acceptance. All copyright restrictions regarding reuse still apply. Cost to participate is US$1500, which must be received before article restriction is lifted.

Reprints. Reprints should be ordered when page proofs are returned; an order form is included with the proofs. Late reprint orders may result in additional fees. Author reprints will be supplied in CMYK color mode because it is a printed medium, but electronic reprints will be supplied in RGB color mode for visualization on screen. There is no extra charge for color reprints. Each coauthor will receive one complimentary electronic (secure PDF) reprint. Additional electronic reprints can be ordered at the time page proofs are returned or at a later date. No hardcopy complimentary reprints are provided.

Proofs. The corresponding author will be contacted by email once proofs are ready, and will be directed to download electronic proofs from a secure website. Electronic page proofs will be provided in RGB, thus reflecting the online quality. Image files will be converted to CMYK for the printed journal; all images published online will be in RGB. Full instructions on completing proof corrections will be provided with the downloaded proof. The author should check the proofs carefully, mark any printer's errors, and answer queries as requested. Author changes should be kept to a minimum. Proof corrections and replacement figures (if any) must be returned within 48 hours to avoid any delay in publication. 

Cover Figure. The cover figure is selected by the Editors from illustrations appearing in the current issue. Authors are encouraged to suggest a figure for consideration or include an additional cover figure submission along with their manuscript submission. Cover figures are published at no charge; cover reprints are available as cover stock reprints or posters (no complimentary cover reprints are provided).

Editorial Communications. All correspondence concerning editorial matters should be addressed to the Editor-in-Chief at The American Journal of Pathology, 9650 Rockville Pike, Bethesda, Maryland, USA 20814-3993, faxed to 301-634-7961, or emailed to ajp@asip.org.Appeals (rebuttals) to editorial decisions must be submitted within 60 days to be considered. Letters to the Editor will be printed at the Editors' discretion in the Correspondence section.

Corrections are published upon request and after editorial review. Retractions are published upon request of authors or their institutions and may also be published by the Journal following a determination of scientific misconduct. Notes of Concern are published in response to editorial concerns relating to scientific or publishing misconduct by authors or reviewers or to alert the scientific community of an ongoing investigation. 
[Revised: January 2013]   
编辑部信息 所在地: 伯明翰 国家 美国   
  Editor-in-Chief:
Kevin A.  Roth , University of Alabama at Birmingham
Senior Associate Editor:
Martha B. Furie, Stony Brook University
Senior Assistant Editors:
John C. Chatham, University of Alabama at Birmingham
Robin G. Lorenz, University of Alabama at Birmingham
Associate Editors:
Chris Albanese, Georgetown University Medical Center
Vincent Castronovo, University of Liege
Robert B. Clarke, University of Manchester
Patricia A. D'Amore, Schepens Eye Research Institute
Lora Hedrick Ellenson, Cornell University
Philippe G. Frank, Thomas Jefferson University
Michael R. Freeman, Children's Hospital Boston/Harvard Medical School
Matthew P. Frosch, Massachusetts General Hospital
Philip Furmanski, Rutgers University
Nisha Jain Garg, University of Texas Medical Branch
Michael S. Goligorsky, New York Medical College
Meera Hameed, Memorial Sloan-Kettering Cancer Center
David M. Hockenbery, Fred Hutchinson Cancer Research Center
Eric P. Hoffman, Children's National Medical Center
Dontscho Kerjaschki, Medical University of Vienna
Andrew A. Lackner, Tulane University
Satdarshan (Paul) S. Monga, University of Pittsburgh School of Medicine
Yasunori Okada, Keio University
Charles A. Parkos, Emory University
Hallgeir Rui, Thomas Jefferson University
Herbert B. Tanowitz, Albert Einstein College of Medicine
Jerrold R. Turner, The University of Chicago
Jouni Uitto, Thomas Jefferson University
Xiao-Ming Yin, Indiana University School of Medicine
Dani S. Zander, Penn State Milton S. Hershey Medical Center 

网友投稿经验整理:
研究方向:分子病理学      审稿时间:约1个月    接收率:约25%     
之前师兄投过一篇,经过3轮review 差不多14个月之后见刊,中间补充过实验,总体来说比较困难。 

我于4月22日投稿,2周后变成decision pending, 再过1周后被拒,此时状态应该还在编辑内审,内审差不多1个月左右。交了$50 submittion fee。
贡献者: snowater
这个杂志要交50美金才审,从投稿细则上看收费很高,版面费,黑白照片,彩色照片都要收费呀。
贡献者:
投出去两周,一直是pre-screen,两天前突然变成decision pending,估计是直接被毙了,等消息吧。
贡献者:
研究方向:分子生物学      审稿时间:约1个月         
审稿速度很慢,编辑手里转悠了2周半,直接被拒了,原因不明,还交了50$
贡献者:jeffreypan
审稿有点慢,一审五个周,修改稿进行了一个月的二审。感觉和hepatology投稿难易程度差不多。
贡献者:64.238.164.115

扫描二维码
关注Pubsci微信
微信公共账号:pubsci888

关键词:论文翻译润色,论文评估,SCI投稿,SCI期刊发表,医生出国进修